Skip to main content
. 2021 Oct 26;118(44):e2107148118. doi: 10.1073/pnas.2107148118

Fig. 1.

Fig. 1.

(A) SEC-MALS profiles of IgA1: overlay of B38-IgA1 (blue line) and H4-IgA1 (orange line); Inset represents SEC isolated H4-IgA1 dimers (∼353 kDa); x axis is retention time (minutes), and y axis is molar mass (grams per mole) (numbers represent B38 variants: ∼152-kDa monomers, ∼349-kDa dimers, and ≥715-kDa oligomers/aggregates). (B) (Left and Middle) Nonreducing gradient gel (4 to 20%, Commassie brilliant blue stained) of purified H4-IgA1 and B38-IgA1 with and without JC (+JC and −JC); m, SEC isolated monomers; d, dimers. H4-IgG1 and B38-IgG1 (IgG1) were used as control. (Right) Representative SDS/PAGE (12%, under reducing conditions) of purified B38-IgA1 (B38) and H4-IgA1 (H4); L, protein ladder. (C) LC-ESI-MS/MS–derived glycosylation profiles of IgA1 and IgG1 produced in ΔXTFT. Bars represent the relative abundance (percent) of glycoforms present at each GS [IgA1: 263NLT and 459NVS, IgG1: 297NST (Fc)]. Nomenclature is according to Consortium for Functional Glycomics.